Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Turn Therapeutics Inc ( (TTRX) ) has provided an update.
On January 7, 2026, Turn Therapeutics Inc. expanded its board from five to six members and appointed veteran healthcare executive Martin Dewhurst as an independent Class III director and chair of the compensation committee, with his term running until the 2028 annual shareholders’ meeting. Dewhurst, who received an initial $100,000 restricted stock unit grant under the company’s 2025 Omnibus Incentive Plan, brings more than three decades of global life sciences and M&A experience from senior roles at McKinsey & Company and ongoing advisory and board positions across healthcare and investment firms, a profile that aligns with Turn Therapeutics’ disciplined, M&A-focused growth strategy and is expected to strengthen its capital allocation, pipeline expansion and partnership efforts; the company simultaneously released a press announcement and updated investor presentation on the same date.
The most recent analyst rating on (TTRX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Turn Therapeutics Inc stock, see the TTRX Stock Forecast page.
Spark’s Take on TTRX Stock
According to Spark, TipRanks’ AI Analyst, TTRX is a Neutral.
The score is held back primarily by weak financial fundamentals (no revenue, persistent losses/cash burn, and negative equity). Technicals show improving near-term price trend but with mixed momentum signals. Corporate events are a positive offset (notably the Medline partnership and clinical/pipeline updates), while valuation remains constrained due to ongoing losses and no dividend.
To see Spark’s full report on TTRX stock, click here.
More about Turn Therapeutics Inc
Turn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing targeted inflammatory and immunology therapies for dermatology, advanced wound care, and infectious diseases. The company has three FDA-cleared proprietary wound and dermatology formulations, is advancing late-stage clinical programs in eczema and onychomycosis, and is also pursuing global health initiatives in thermostable vaccine delivery for underserved regions.
Average Trading Volume: 454,151
Current Market Cap: $139.3M
See more insights into TTRX stock on TipRanks’ Stock Analysis page.